The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's Disease

被引:95
作者
Torlakovic, E [1 ]
Tierens, A [1 ]
Dang, HD [1 ]
Delabie, J [1 ]
机构
[1] Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway
关键词
D O I
10.1016/S0002-9440(10)63027-1
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Hodgkin's disease (HD) is a lymphoproliferative disease of predominantly B-cell origin. However, the reasons for the incomplete development of the B-cell phenotype and lack of immunoglobulin expression in classical HD (cHD) have not been fully explained. We examined the expression of PU.1 in HD, an Ets-family transcription factor, which regulates the expression of immunoglobulin and other genes that are important for B-cell development. Immunohistochemistry for PU.1 was performed on 35 cases of cHD and 15 cases of lymphocyte predominance HD as well as 67 non-Hodgkin's lymphomas (NHL). Expression of PU.1 was studied by Western blotting in four cHD-derived cell lines and in five NHL cell lines. We also studied the expression of two additional B-cell transcription factors, B-cell-specific activator protein and Oct-2. Our results show a striking lack of PU.1 expression by neoplastic cells in cHD but not in lymphocyte predominance RD. Our study also confirmed that B-cell-specific activator protein but not Oct-2 is not expressed by cHD. Western blotting showed no PU.1 protein expression in the cHD-derived cell fines, with the exception of one cell line of putative monocyte/histiocyte origin. The lack of PU.1 protein expression in cHD likely contributes to the lack of immunoglobulin expression and incomplete B-cell phenotype characteristic of the Reed-Sternberg cells in cHD.
引用
收藏
页码:1807 / 1814
页数:8
相关论文
共 56 条
[31]  
NADKARNI JS, 1969, CANCER, V23, P64, DOI 10.1002/1097-0142(196901)23:1<64::AID-CNCR2820230107>3.0.CO
[32]  
2-M
[33]   REGULATION OF LYMPHOID-SPECIFIC IMMUNOGLOBULIN-MU HEAVY-CHAIN GENE ENHANCER BY ETS-DOMAIN PROTEINS [J].
NELSEN, B ;
TIAN, G ;
ERMAN, B ;
GREGOIRE, J ;
MAKI, R ;
GRAVES, B ;
SEN, R .
SCIENCE, 1993, 261 (5117) :82-86
[34]  
Nishii K, 2000, INT J HEMATOL, V71, P372
[35]   Clonality in nodular lymphocyte-predominant Hodgkin's disease [J].
Ohno, T ;
Stribley, JA ;
Wu, G ;
Hinirichs, SH ;
Weisenburger, DD ;
Chan, WC .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (07) :459-465
[36]   The role of Ets family transcription factor PU.1 in hematopoietic cell differentiation, proliferation and apoptosis [J].
Oikawa, T ;
Yamada, T ;
Kihara-Negishi, F ;
Yamamoto, H ;
Kondoh, N ;
Hitomi, Y ;
Hashimoto, Y .
CELL DEATH AND DIFFERENTIATION, 1999, 6 (07) :599-608
[37]  
PETTERSSON M, 1995, BLOOD, V86, P2747
[38]   PU-1 RECRUITS A 2ND NUCLEAR FACTOR TO A SITE IMPORTANT FOR IMMUNOGLOBULIN-KAPPA-3' ENHANCER ACTIVITY [J].
PONGUBALA, JMR ;
NAGULAPALLI, S ;
KLEMSZ, MJ ;
MCKERCHER, SR ;
MAKI, RA ;
ATCHISON, ML .
MOLECULAR AND CELLULAR BIOLOGY, 1992, 12 (01) :368-378
[39]   PU.1 can participate in an active enhancer complex without its transcriptional activation domain [J].
Pongubala, JMR ;
Atchison, ML .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (01) :127-132
[40]  
Re D, 2001, CANCER RES, V61, P2080